title: Effects of adrenaline infusion on plasma lipids and noradrenaline levels in rabbits with adriamycin-induced cardiomyopathy.
abstract: 1. We investigated the acute effects of adrenaline infusion on plasma lipid levels in vehicle- and adriamycin-treated rabbits. Lipids were measured before and 30 and 60 min after the commencement of continuous intravenous administration of adrenaline (0.06 microgram/kg per min) or saline in pentobarbital-anaesthetized rabbits. 2. Adrenaline infusion significantly increased plasma free fatty acid (P < 0.05) and noradrenaline (NA) levels (P < 0.05) in vehicle-treated control rabbits, but not in adriamycin-treated rabbits. However, adrenaline had no effect on plasma total cholesterol, free cholesterol, high-density lipoprotein-cholesterol, triglyceride or phospholipid levels. 3. Pretreatment with propranolol almost completely inhibited increased plasma free fatty acid and NA levels associated with adrenaline infusion, suggesting that adrenaline increases plasma free fatty acid and NA levels via the stimulation of beta-adrenoceptors in vehicle-treated rabbits. 4. It is suggested that both the production of plasma free fatty acids and the release of NA via the activation of beta-adrenoceptors is reduced in rabbits with adriamycin-induced cardiomyopathy. This may be related to the down-regulation of beta-adrenoceptors caused by elevated plasma NA levels induced by cardiac failure.
authors.affiliation: 2nd Department of Internal Medicine, Gifu University School of Medicine, Japan. gotohk-gif@umin.u-tokyo.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Minatoguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Uno
authors.forename: M
authors.initials: M
authors.lastname: Seishima
authors.forename: M
authors.initials: M
authors.lastname: Koshiji
authors.forename: M
authors.initials: M
authors.lastname: Kakami
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004317:Doxorubicin / Q000009:adverse effects*; D004837:Epinephrine / Q000097:blood / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D009638:Norepinephrine / Q000097:blood*; D010743:Phospholipids / Q000097:blood; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D010743:Phospholipids; D011943:Receptors, Adrenergic, beta; D014280:Triglycerides; D004317:Doxorubicin; D002784:Cholesterol; D011433:Propranolol; D009638:Norepinephrine; D004837:Epinephrine